Recurrent venous thromboembolism

American Family Physician

Volumn 83, Issue 3, 2011, Pages 293-300

  Galioto, Nicholas J ^a   Danley, Dana L ^b   van Maanen, Ryan J ^a  

^a BROADLAWNS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; LOW MOLECULAR WEIGHT HEPARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CANCER PATIENT; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; HUMAN; LABORATORY TEST; LONG TERM CARE; PRACTICE GUIDELINE; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SCREENING; THROMBOPHILIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; REVIEW;

ANTICOAGULANTS; HUMANS; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 79953134004     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Zhu T, Martinez I, Emmerich J. Venous thromboembo-lism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298-310.
2. Prandoni P, Lensing A.W, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7.
3. Christiansen S.C, Cannegieter S.C, Koster T, Vanden-broucke J.P, Rosendaal F.R., Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352-2361.
4. Kearon C, Kahn S.R, Agnelli G, Goldhaber S, Raskob G.E, Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) [published correction appears in Chest. 2008;134(4):892]. Chest. 2008;133(6 suppl):454S-545S.
5. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloprolifera-tive disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129(4):553-560.
6. Mahmoodi B.K, ten Kate M.K, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008;117(2):224-230.
7. Bates S.M, Greer I.A, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):844S-886S.
8. Chandra D, Parisini E, Mozaffarian D. Meta-analysis: travel and risk for venous thromboembolism. Ann Intern Med. 2009;151(3):180-190.
9. Kearon C. Long-term management of patients after venous thromboembolism. Circulation. 2004;110(9 suppl 1):I10-I18.
10. Pernod G, Biron-Andreani C, Morange P.E, et al.; French group on haemostasis and thrombosis; French Society of vascular medicine. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc. 2009;34(3): 156-203.
11. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523-526.
12. Ho W.K, Hankey G.J, Quinlan D.J, Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729-736.
13. Garcia D. Duration of anticoagulant therapy for patients with venous thromboembolism. Thromb Res. 2008;123(suppl 1):S62-S64.
14. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92(2):199-205.
15. Schulman S, Rhedin A.S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembo-lism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332(25):1661-1665.
16. Hansson P.O, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6):769-774.
17. Martinelli I, Mannucci P.M, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92(7):2353-2358.
18. Forastiero R.R, Martinuzzo M.E, Cerrato G.S, Kordich L.C, Carreras L.O. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost. 1997;78(3):1008-1014.
19. Segal J.B, Brotman D.J, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous throm-boembolism. Evid Rep Technol Assess (Full Rep). 2009 (180):1-162.
20. Cohn D, Vansenne F, de Borgie C, Middeldorp S. Throm-bophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2009; (1):CD007069.
21. Simpson E.L, Stevenson M.D, Rawdin A, Papaioannou D. Thrombophilia testing in people with venous throm-boembolism: systematic review and cost-effectiveness analysis. Health Technol Assess. 2009;13(2):1-91.
22. Guyatt G.H, Cook D.J, Jaeschke R, Pauker S.G, Schüne-mann H.J. Grades of recommendation for antithrombotic agents: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) [published correction appears in Chest. 2008;134(2):473]. Chest. 2008;133(6 suppl):123S-131S.
23. Hirsh J, Guyatt G, Albers G.W, Harrington R, Schüne-mann H.J. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) [published correction appears in Chest. 2008;134(4):892]. Chest. 2008;133(6 suppl):71S-109S.
24. Baglin T, Barrowcliffe T.W, Cohen A, Greaves M, British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133(1):19-34.
25. Moll S, Ortel T.L. Monitoring warfar in therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127 (3):177-185.
26. Kato S, Chernyavsky S, Tokita J.E, et al. Relationship between proteinuria and venous thromboembolism [published ahead of print February 16, 2010.] J Thromb Thrombolysis. http://www.springerlink.com/content/w4r2304r35529030/ (subscription required). Accessed September 21, 2010.
27. McBane R.D., Wysokinski W.E. Treatment of venous thrombosis at unusual sites. Curr Treat Options Cardio-vasc Med. 2008;10(2):136-145.
28. Chan M.Y, Becker R.C. Identifcation and treatment of arterial thrombophilia. Curr Treat Options Cardiovasc Med. 2008;10(1):3-11.
29. Verhovsek M, Douketis J.D, Yi Q, et al. Systematic review: d-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboem-bolism. Ann Intern Med. 2008;149(7):481-490, W94.
30. Prandoni P, Lensing A.W, Prins M.H, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12): 955-960.
31. Cosmi B, Legnani C, Iorio A, et al.; PROLONG Investigators. Residual venous obstruction, alone and in combination with d-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg. 2010;39(3):356-365.
32. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
33. Piccioli A, Lensing A.W, Prins M.H, et al.; SOMIT Investigators Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2(6):884-889.
34. Sørensen H.T, Mellemkjaer L, Olsen J.H, Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850.
35. Paneesha S, McManus A, Arya R, et al.; VERITY Investigators. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost. 2010;103(2):338-343.
36. Monreal M, Lensing A.W, Prins M.H, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost. 2004; 2(6):876-881.
37. Trujillo-Santos J, Prandoni P, Rivron-Guillot K, et al.; RIETE Investigators. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost. 2008; 6(2):251-255.
38. Carrier M, Le Gal G, Wells P.S, Fergusson D, Ramsay T, Rodger M.A. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149(5):323-333.
39. Lee A.Y, Levine M.N, Baker R.I, et al.; Randomized Comparison of Low-Molecular-Weight Heparin Versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
40. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians [published correction appears in Ann Fam Med. 2007;5(2):179]. Ann Fam Med. 2007;5(1):74-80.